Farnam Financial’s Bio-Rad Laboratories Class A BIO Stock Holding History

Farnam Financial’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$227K	Sell	773 -375	-33%	-$106K	0.17%	51
2026 Q1	$320K	Sell	1,148 -1,190	-51%	-$343K	0.26%	42
2025 Q4	$708K	Sell	2,338 -165	-7%	-$51.5K	0.53%	34
2025 Q3	$702K	Sell	2,503 -1,291	-34%	-$351K	0.55%	33
2025 Q2	$916K	Sell	3,794 -1,247	-25%	-$295K	0.82%	30
2025 Q1	$1.23M	Sell	5,041 -1,463	-22%	-$440K	1.25%	21
2024 Q4	$2.14M	Sell	6,504 -293	-4%	-$99.5K	2.23%	12
2024 Q3	$2.27M	Buy	+6,797	New	+$2.16M	2.5%	9

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Farnam Financial's BIO Position: Q2 2026 in Review

Farnam Financial reduced its Bio-Rad Laboratories Class A (BIO) stake by 33% in Q2 2026, selling an estimated $106K and leaving 773 shares worth $227K. The position accounts for 0.17% of the portfolio, ranked #51.

Farnam Financial first reported a position in BIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.27M in Q3 2024. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Farnam Financial held 773 shares of Bio-Rad Laboratories Class A worth $227K as of Q2 2026.
Farnam Financial sold 375 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $106K.
Bio-Rad Laboratories Class A made up 0.17% of Farnam Financial's portfolio in Q2 2026, its #51 holding.
Farnam Financial first reported a position in Bio-Rad Laboratories Class A in Q3 2024 and has held it in 8 quarters since.
Farnam Financial's Bio-Rad Laboratories Class A position peaked at $2.27M in Q3 2024.
399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Farnam Financial's 13F filing for Q2 2026, filed 22 Jul 2026.